Protocol for a randomized, placebo-controlled, double-blind phase IIa study of the safety, tolerability, and symptomatic efficacy of the ROCK-inhibitor Fasudil in patients with Parkinson's disease (ROCK-PD).

"Conflict of interest PL is an inventor on a patent for the use of Fasudil for the treatment of Amyotrophic lateral sclerosis (EP 2825175 B1, US 9.980972 B2). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."

"The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study is funded by the German Federal Ministry of Education and Research (BMBF) under grant number 01EN2005. PL is further supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145, SyNergy – ID 390857198)."